Latest Breaking News On - Inhibikase therapeutic - Page 1 : comparemela.com

Inhibikase s risvodetinib wins FDA orphan drug designation - Pharmaceutical Technology

Inhibikase is planning a Phase II trial to investigate its Abelson Tyrosine Kinase inhibitor in MSA.

Shutterstock andrii vodolazhskyiMilton wernerCompany profilesCompany profileDrug administrationMovement disorder societyInhibikase therapeuticAbelson tyrosine kinaseChief executiveInhibikase therapeuticsAlterity therapeutics

Pharmaceutical Technology

Pharmaceutical Technology
pharmaceutical-technology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-technology.com Daily Mail and Mail on Sunday newspapers.

Milton wernerDrug administrationMovement disorder societyInhibikase therapeuticAbelson tyrosine kinaseChief executiveInhibikase therapeuticsAlterity therapeutics

New Parkinson s drug formulation nearly doubles exposure

New Parkinson s drug formulation nearly doubles exposure
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Milton wernerNew parkinsonAbelson tyrosine kinaseInhibikase therapeuticInhibikase therapeuticsInvestigational new drug

Inhibikase Therapeutics, Inc to Post Q2 2023 Earnings of ($0 15) Per Share, HC Wainwright Forecasts (NYSE:IKT)

Inhibikase Therapeutics, Inc. (NYSE:IKT – Get Rating) – Stock analysts at HC Wainwright raised their Q2 2023 earnings per share estimates for shares of Inhibikase Therapeutics in a research report issued on Tuesday, May 16th. HC Wainwright analyst E. White now forecasts that the company will earn ($0.15) per share for the quarter, up from […]

Armistice capitalRenaissance technologiesVanguard group incBlair william coInhibikase therapeutics incInhibikase therapeuticsGet ratingInhibikase therapeuticLane advisorsVanguard groupInhibikase therapeutics dailyNyse iktEarnings estimatesHc wainwright

Reviewing Finch Therapeutics Group (NASDAQ:FNCH) & Inhibikase Therapeutics (NYSE:IKT)

Finch Therapeutics Group (NASDAQ:FNCH – Get Rating) and Inhibikase Therapeutics (NYSE:IKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk. Insider and Institutional Ownership 22.7% of Finch Therapeutics […]

United statesJohns hopkins universityInhibikase therapeutics incInhibikase therapeutics company profile get ratingTakeda pharmaceutical companyFinch therapeutics groupFinch therapeutics group company profile get ratingFinch therapeutics group incUniversity of minnesotaMemorial sloan kettering cancer centerSkysong innovationsLouisiana state university school of medicineGet ratingInhibikase therapeuticsTherapeutics groupGiven inhibikase therapeutic